Cargando…

A complementary new drug for PNH

Detalles Bibliográficos
Autor principal:	Brodsky, Robert A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555420/ https://www.ncbi.nlm.nih.gov/pubmed/32191798 http://dx.doi.org/10.1182/blood.2020004959

Ejemplares similares

Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission
por: Sukumar, Senthil, et al.
Publicado: (2022)

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab
por: Kulasekararaj, Austin G., et al.
Publicado: (2021)

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
por: Kanapuru, Bindu, et al.
Publicado: (2022)

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)

Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study
por: Haverkos, Bradley, et al.
Publicado: (2023)

A feasibility randomized controlled trial of an mHealth app vs booklets for patient-facing guidelines in adults with SCD
por: Cronin, Robert M., et al.
Publicado: (2023)

Characteristics of Taiwanese patients of PNH in the international PNH registry
por: Chou, Wen-Chien, et al.
Publicado: (2016)

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
por: Fleming, Megan, et al.
Publicado: (2022)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

Unraveling the pathophysiology of lower-limb postthrombotic syndrome in adolescents: a proof-of-concept study
por: Avila, M. Laura, et al.
Publicado: (2023)

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study
por: Maese, Luke, et al.
Publicado: (2023)

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
por: Allen, Pamela B., et al.
Publicado: (2022)

Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study
por: Van Der Valk, Paul, et al.
Publicado: (2022)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
por: Quinn, Charles T., et al.
Publicado: (2022)

External validation of the PEGeD diagnostic algorithm for suspected pulmonary embolism in an independent cohort
por: Robert-Ebadi, Helia, et al.
Publicado: (2022)

Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
por: Hamilton, Betty K., et al.
Publicado: (2023)

Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial
por: Namazzi, Ruth, et al.
Publicado: (2023)

Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial
por: Hsu, Peter, et al.
Publicado: (2021)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia
por: Kreitman, Robert J., et al.
Publicado: (2023)

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
por: Johnsrud, Andrew, et al.
Publicado: (2021)

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity
por: Courjon, Johan, et al.
Publicado: (2021)

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
por: Chihara, Dai, et al.
Publicado: (2021)

Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria
por: Henrici, Ryan C., et al.
Publicado: (2021)

Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant
por: Bartlett, Allison L., et al.
Publicado: (2023)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome
por: Jacobson, Caron A., et al.
Publicado: (2023)

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
por: de Botton, Stéphane, et al.
Publicado: (2022)

Hematologic complications with age in Shwachman-Diamond syndrome
por: Furutani, Elissa, et al.
Publicado: (2022)

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022)

More intensive therapy has a better effect for frail parents with multiple myeloma
por: DuMontier, Clark, et al.
Publicado: (2023)

Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries
por: Jiao, Boshen, et al.
Publicado: (2023)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI
por: Khorana, Alok A., et al.
Publicado: (2022)

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
por: Vijenthira, Abi, et al.
Publicado: (2020)

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
por: Tran, Misha C., et al.
Publicado: (2022)

Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study
por: Abel, Gregory A., et al.
Publicado: (2023)

Comparison of the effectiveness and safety of direct oral anticoagulants: a nationwide propensity score–weighted study
por: Ingason, Arnar B., et al.
Publicado: (2022)

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
por: Daver, Naval G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aj2c0hgs8rt7roqrgm431nhclf